Increased bladder apoptosis with α-1 adrenoceptor antagonists in benign prostatic hyperplasia

被引:2
|
作者
Erdogru, T
Gülkesen, KH
Kukul, E
Yalçinkaya, M
Karpuzoglu, G
Baykara, M
机构
[1] Akdeniz Univ, Fac Med, Dept Urol, TR-07070 Antalya, Turkey
[2] Akdeniz Univ, Fac Med, Dept Pathol, TR-07070 Antalya, Turkey
来源
关键词
alpha-adrenoceptor antagonists; apoptosis; benign prostatic hyperplasia; bladder;
D O I
10.1080/003655902320131857
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine whether preoperative usage of alpha-1 adrenoceptor antagonists (alpha-1ARA) prevents the alterations in bladder wall components due to obstruction via changing apoptotic and/or proliferative activity and provides an advantage for improvement of irritative symptoms following removement of bladder outlet obstruction. Material and Methods: A total of 39 patients were enrolled to the present study. According to preoperative medical treatment, patients were divided into 2 groups as preoperative untreated (n = 15) and medically treated patients with alpha-1ARA (n = 24). Apoptotic and proliferative indices of bladder wall were determined with TUNEL assay and proliferating cell nuclear antigen immunoreactivity, respectively. Results: While the mean apoptotic indexes (AI) of lamina propria were 0.293 +/- 0.163 vs 0.978 +/- 0.194 in untreated and treated patients, the mean AI of myofibroblast cells were 0.10 +/- 0.06 and 0.90 +/- 0.23 in untreated and treated patients, respectively. There were statistically significant differences between lamina propria (p = 0.0067) and myofibroblast cells (p = 0.0280) AI in the two groups. However, there were no significant differences between postoperative symptom indices in preoperatively treated and untreated groups. Conclusions: alpha1-ARA treatment might have an effect on hypertrophy and supersensitivity of bladder wall due to increased outlet obstruction via prevention of the imbalance between cell proliferation and apoptosis, providing normal homeostatic control mechanisms, through the interval between the onset of the lower urinary tract symptoms and time surgical intervention. However, further studies should be organized to demonstrate the impact of long-term alpha1-ARA medication for post-operative significant improvement on irritative symptom index.
引用
收藏
页码:188 / 193
页数:6
相关论文
共 50 条
  • [21] Expression of α1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective α1-adrenoceptor antagonists in the management of benign prostatic hyperplasia
    Kojima, Yoshiyuki
    Sasaki, Shoichi
    Kubota, Yasue
    Hayase, Masa
    Hayashi, Yutaro
    Shinoura, Hitomi
    Tsujimoto, Gozoh
    Kohri, Kenjiro
    JOURNAL OF UROLOGY, 2008, 179 (03): : 1040 - 1046
  • [22] Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia
    Lowe, F
    PROSTATE CANCER AND PROSTATIC DISEASES, 1999, 2 (03) : 110 - 119
  • [23] UROSELECTIVE ALPHA(1)-ADRENOCEPTOR ANTAGONISTS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERTROPHY
    GEORGE, P
    BORG, F
    OCONNOR, S
    LECHAIRE, J
    ARBILLA, S
    PIMOULE, C
    GRAHAM, D
    WEDZIKOWSKY, T
    LANGER, SZ
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1995, 30 : S299 - S310
  • [24] Discovery of novel potent and selective alpha(1A) adrenoceptor antagonists for the symptomatic treatment of benign prostatic hyperplasia (BPH)
    Meyer, MD
    Altenbach, RJ
    Basha, FZ
    Carroll, WA
    Drizin, I
    Ehrlich, PP
    Elmore, SW
    Lebold, SA
    Sippy, KB
    Tietje, K
    Wendt, MD
    Hancock, AA
    Brune, ME
    Buckner, SA
    Kerwin, JF
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 291 - MEDI
  • [25] Selectivity at the molecular level of the classical and newer alpha(1)-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia: The concept of uroselectivity
    Graham, D
    Arbilla, S
    Pimoule, C
    Langer, SZ
    EUROPEAN UROLOGY, 1996, 29 (03) : 378 - 379
  • [26] Uroselectivity of alpha-1 adrenergic antagonists in benign prostatic hyperplasia
    Jolliet, P
    Bourin, M
    THERAPIE, 1998, 53 (01): : 61 - 66
  • [28] Benign prostatic hyperplasia mimicking bladder tumor
    Hsu, TH
    Matin, SF
    UROLOGY, 2001, 57 (06) : 1166 - 1166
  • [29] Clinical significance of α1-adrenoceptor selectivity in the management of benign prostatic hyperplasia
    Pool J.L.
    Kirby R.S.
    International Urology and Nephrology, 2001, 33 (3) : 407 - 412
  • [30] A new α1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia
    Nature Clinical Practice Urology, 2007, 4 (2): : 64 - 65